Ivacorlan

Ivabradine, the active ingredient in Ivacorlan, is a If channel inhibitor presented as an oral tablet for oral use. It reduces heart rate and is indicated for patients with chronic stable angina and for those with heart failure with reduced ejection fraction. By selectively inhibiting the funny current in the sinoatrial node, it lowers heart rate without decreasing myocardial contractility, helping to alleviate anginal symptoms and improve cardiac efficiency.

GNH USA supplies Ivacorlan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivacorlan is used in cardiovascular conditions that benefit from heart‑rate reduction.

- Chronic stable angina: improves exercise tolerance and reduces the frequency of angina attacks. - Heart failure with reduced ejection fraction: lowers heart rate, contributing to better ventricular remodeling and reduced risk of hospitalization. - Stable angina pectoris: decreases the number of chest pain episodes during daily activities.

Adverse reactions may occur with Ivacorlan and are categorized by frequency.

Common Side Effects: - Bradycardia: heart rate slower than expected. - Visual disturbances (phosphenes): transient luminous phenomena. - Headache: mild to moderate intensity. - Dizziness or vertigo. - Fatigue or general weakness.

Serious or Rare Side Effects: - Severe bradycardia requiring medical intervention. - Atrial fibrillation or other significant arrhythmias. - Symptomatic hypotension. - High‑grade atrioventricular block. - Severe visual impairment or persistent photopsia. - Allergic reactions such as rash, angioedema, or anaphylaxis.

Before initiating therapy, clinicians should consider several safety measures.

- Heart‑rate monitoring: ensure baseline rate is ≥60 bpm before starting. - Hepatic function: avoid in patients with severe hepatic impairment. - Concomitant bradycardic agents: use caution when combined with beta‑blockers, digoxin, or calcium‑channel blockers. - Sick‑sinus syndrome or AV block: contraindicated unless a pacemaker is present. - CYP3A4 inhibitors: assess potential for increased plasma levels. - Store below 25°C: keep in the original container, protect from moisture and light.

Ivacorlan may interact with other medicines, requiring attention to the level of risk.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): can markedly increase ivabradine exposure. - Concurrent use with other heart‑rate‑lowering drugs (beta‑blockers, digoxin, non‑dihydropyridine calcium‑channel blockers): may cause severe bradycardia. - Pacemaker‑dependent patients receiving ivabradine without appropriate device settings.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, clarithromycin): may raise plasma levels. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Drugs that prolong QT interval (e.g., amiodarone, sotalol): monitor ECG for additive effects.